Skip to main content

Table 1 Hemodynamic variables in the three groups at the different study time-points

From: Myocardial effects of angiotensin II compared to norepinephrine in an animal model of septic shock

Variables

 

Baseline

Septic

Fluids

Vasopressor 1

Vasopressor 2

Mean ± SD

  

Shock

   

HR (/min)

NE

87 ± 15

153 ± 18

133 ± 14

146 ± 16

151 ± 16

 

Ang II

91 ± 15

153 ± 11

132 ± 11

154 ± 10

147 ± 20

CO (mL/min/kg)

NE

107 ± 21

70 ± 17

142 ± 29

173 ± 32

174 ± 36

 

Ang II

113 ± 11

68 ± 11

143 ± 23

171 ± 33

170 ± 36

SV (mL/kg)

NE

1.2 ± 0.2

0.4 ± 0.1

1.1 ± 0.2

1.2 ± 0.2

1.2 ± 0.2

 

Ang II

1.2 ± 0.1

0.4 ± 0.1

1.0 ± 0.1

1.1 ± 0.2

1.2 ± 0.2

MAP (mmHg)

NE

74 ± 7

49 ± 3

58 ± 5

68 ± 3

68 ± 3

 

Ang II

76 ± 8

49 ± 2

55 ± 4

68 ± 2

69 ± 4

LVEDV (mL)

NE

155 ± 45

 

143 ± 40

124 ± 31

132 ± 37

 

Ang II

151 ± 50

 

154 ± 17

127 ± 31

152 ± 40

LVESV (mL)

NE

90 ± 28

 

70 ± 20

56 ± 18

62 ± 14

 

Ang II

91 ± 42

 

93 ± 19

75 ± 25

80 ± 29

LVEDP (mmHg)

NE

12 ± 1

 

19 ± 5

16 ± 4

16 ± 6

 

Ang II

11 ± 3

 

17 ± 8

18 ± 8

19 ± 8

TauLog (ms)

NE

20 ± 3

 

13 ± 4

11 ± 2

12 ± 6

 

Ang II

19 ± 3

 

15 ± 8

12 ± 2

12 ± 6

V30 (mL)

NE

193 ± 56

 

153 ± 27

143 ± 40

146 ± 28

 

Ang II

191 ± 59

 

172 ± 23

152 ± 35

164 ± 29

Chamber stiffness constant β (milliliters−1)

NE

0.04 ± 0.02

 

0.07 ± 0.03

0.06 ± 0.02

0.07 ± 0.03

 

Ang II

0.04 ± 0.02

 

0.06 ± 0.03

0.05 ± 0.03

0.04 ± 0.02

dP/dTmax (mmHg/s)

NE

1838 ± 246

1870 ± 246

1860 ± 427

6198 ± 1827*

6491 ± 1809*

 

Ang II

1766 ± 1050

1832 ± 512

2088 ± 875

2953 ± 1044

3437 ± 1044

dP/dTmax/EDV ratio

NE

10.2 ± 4.8

 

12.4 ± 5.6

35.4 ± 8.6*

36.7 ± 12*

 

Ang II

12.7 ± 8.3

 

8.9 ± 2.4

20.1 ± 7.7*

17.3 ± 3.74*

PRSW (mmHg)

NE

57 ± 20

 

57 ± 17

101 ± 21*

98 ± 38

 

Ang II

48 ± 20

 

63 ± 15

85 ± 13

78 ± 12

Emax (mmHg/mL)

NE

0.7 ± 0.3

 

0.9 ± 0.3

1.6 ± 0.7

1.4 ± 0.9

 

Ang II

0.8 ± 0.3

 

0.9 ± 0.2

1.2 ± 0.4

0.8 ± 0.2

V0 (mL)

NE

− 37 ± 16

 

− 25 ± 23

− 36 ± 26

− 30 ± 40

 

Ang I

− 27 ± 27

 

− 31 ± 52

− 37 ± 36

− 55 ± 37

V100 (mL)

NE

104 ± 26

 

87 ± 14

49 ± 19

51 ± 11

 

Ang II

96 ± 41

 

108 ± 11

83 ± 40

65 ± 23

Ea (mmHg/mL)

NE

1.5 ± 0.2

 

1.6 ± 0.3

1.8 ± 0.8

2.1 ± 0.8

 

Ang II

1.4 ± 0.3

 

1.5 ± 0.2

1.8 ± 0.4

1.6 ± 0.3

Ea/Emax ratio

NE

1.8 ± 1

 

1.7 ± 0.7

1.3 ± 0.6

1.6 ± 0.3

 

Ang II

1.5 ± 0.5

 

2.2 ± 1.1

1.7 ± 0.6

2.0 ± 0.5

EF (%)

NE

40 ± 13

 

39 ± 10

49 ± 17

47 ± 8

 

Ang II

46 ± 16

 

35 ± 7

47 ± 10

44 ± 10

RAP (mmHg)

NE

11 ± 1

10 ± 1

13 ± 2

13 ± 3

14 ± 3

 

Ang II Sham

9 ± 2

11 ± 2

12

12 ± 2

12 ± 2

mPAP (mmHg)

NE

22 ± 2

25 ± 4

29 ± 5

29 ± 5

29 ± 5

 

Ang II

24 ± 4

26 ± 5

28 ± 3

29 ± 3

29 ± 3

  1. PV loop analysis was obtained at baseline, fluids, vasopressor 1 and vasopressor 2
  2. HR, heart rate; MAP, mean arterial pressure; SV, stroke volume; CO, cardiac output; RAP, right atrial pressure; LVEDV, left ventricular end diastolic volume; LVESV, left ventricular end systolic volume; LVEDP, left ventricular end diastolic pressure; EF, ejection fraction; PRSW, preload recruitable stroke work; Emax, left ventricular maximal elastance; Ea, effective arterial elastance; Ea/Emax, left ventriculo-arterial coupling; V30, LV volume at 30 mmHg on the End Diastolic Pressure Volume Relationship; V0, LV volume at 0 mmHg on the End Systolic Pressure Volume Relationship; V100, LV volume at 100 mmHg on the End Systolic Pressure Volume Relationship; NE, norepinephrine; Ang, angiotensin
  3. *p value < 0.05 between NE and Ang II
Back to article page

Critical Care

ISSN: 1364-8535